16
Views
5
CrossRef citations to date
0
Altmetric
Review

Preconception planning to reduce the risk of perinatal depression and anxiety disorders

, , &
Pages 421-435 | Published online: 10 Jan 2014

References

  • Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA295(5), 499–507 (2006).
  • Dannon PN, Iancu I, Lowengrub K et al. Recurrence of panic disorder during pregnancy: a 7-year naturalistic follow-up study. Clin. Neuropharmacol.29, 132–137 (2006).
  • Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR. Obsessive–compulsive symptoms in pregnancy and the puerperium: a review of the literature. J. Anxiety Disord.17, 461–478 (2003).
  • Alcorn KL, O’Donovan A, Patrick JC et al. A prospective longitudinal study of the prevalence of post-traumatic stress disorder resulting from childbirth events. Psychol. Med. DOI: 10.1017/S0033291709992224 (2010) (Epub ahead of print).
  • Dennis CL. Psychosocial and psychological interventions for prevention of postnatal depression: systematic review. Br. Med. J.331(7507), 1–8 (2005).
  • Howard LM, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of perinatal depression. Cochrane Database Syst Rev.2, CD004363 (2005).
  • Brent D. Rapporteurs: A Study of Interactions: Emerging Issues in the Science of Adolescence Workshop Summary. Beatty A, Chalk R (Eds). National Academics Press, Washington DC, USA, 16 (2006).
  • Lindgren K. Relationships among maternal–fetal attachment, prenatal depression, and health practices in pregnancy. Res. Nurs. Health24(3), 203–217 (2001).
  • Zuckerman B, Amaro H, Bauchner H et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am. J. Obstet. Gynecol.160(5 Pt 1), 1107–1111 (1989).
  • Anderson L, Sundstrom-Poromaa I, Wulff M et al. Implications of antenatal depression and anxiety for obstetric outcome. Obstet. Gynecol.104(3), 467–476 (2004).
  • Rahman A, Buin J, Loval H et al. Association between antenatal depression and low birthweight in a developing country. Acta Psychiatr. Scand.115(6), 481–486 (2007).
  • Rogal SS, Poschman K, Belanger K et al. Effects of posttraumatic stress disorder on pregnancy outcomes. J. Affect. Disord.102(1–3), 137–143 (2007).
  • Li D, Liu L, Odoull R. Presence of depressive symptoms during early pregnancy and the risks of preterm delivery: a prospective cohort study. Hum. Reprod.24(1), 146–153 (2009).
  • Maina G, Saracco P, Giolito MR et al. Impact of maternal psychological distress on fetal weight, prematurity and intrauterine growth retardation. J. Affect. Disord.111(2–3), 214–220 (2008).
  • Zuckerman B, Bauchner H, Parker S et al. Maternal depressive symptoms during pregnancy, and newborn irritability. J. Dev. Behav. Pediatr.11(4), 190–194 (1990).
  • Huot RL, Brennan PA, Stowe ZN et al. Negative affect in offspring of depressed mothers is predicted by infant cortisol levels at 6 months and maternal depression during pregnancy, but not postpartum. Ann. NY Acad. Sci.1032, 234–236 (2004).
  • Van den Berg BRH, Marcoen A. High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems and anxiety in 8 and 9 year olds. Child Dev.75, 1085–1097 (2004).
  • O’Connor TG, Caprariello P, Blackmore ER et al. Prenatal mood disturbance predicts sleep problems in infancy and toddlerhood. Early Hum. Dev.83(7), 451–458 (2007).
  • Friedman SH, Resnick PJ. Postpartum depression: an update. Womens Health (Lond. Engl.)5(3), 287–295 (2009).
  • Dennis CL, McQueen K. The relationship between infant-feeding outcomes and postpartum depression: a qualitative systematic review. Pediatrics123(4), 736–751 (2009).
  • Soares DN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability. J. Psychiatry Neurosci.33(4), 331–343 (2007).
  • Bloch M, Rotenberg N, Koren D, Klein E. Risk factors associated with the development of postpartum mood disorders. J. Affect. Disord.88, 9–18 (2005).
  • Correia LL, Linhares MBM. Maternal anxiety in the pre- and post-natal period: a literature review. Rev. Lat. Am. Enfermagem.15(4), 677–683 (2007).
  • Bloch M, Rotenberg N, Koren D, Klein E. Risk factors for early postpartum depressive symptoms. Gen. Hosp. Psychiatry28, 3–8 (2006).
  • Beck CT. Predictors of postpartum depression: an update. Nurs. Res.50(5), 275–285 (2001).
  • Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen. Hosp. Psychiatry26, 289–295 (2004).
  • Altemus M, Fong J, Yang R et al. Changes in cerebrospinal fluid neurochemistry during pregnancy. Biol. Psychiatry56(6), 386–392 (2004).
  • American College of Obstetricians and Gynecologists. Psychosocial risk factors: perinatal screening and intervention. ACOG Committee Opinion No. 343. Obstet. Gynecol.108(2), 469–477 (2006).
  • O’Donnell K, O’Connor TG, Glover V. Prenatal stress and neurodevelopment of the child: focus on the HPA axis and the role of the placenta. Dev. Neurosci.31(4), 285–292 (2009).
  • Beddoe AE, Paul Yang CP, Kennedy HP, Weiss SJ, Lee KA. The effects of mindfulness-based yoga during pregnancy on maternal psychological and physical distress. J. Obstet. Gynecol. Neonat. Nurs.38(3), 310–319 (2009).
  • Urizar GG, Milazzo M, Le HN, Delucchi K, Sotelo R, Munoz RF. Impact of stress reduction instructions on stress and cortisol levels during pregnancy. Biol. Psychol.67, 275–282 (2004).
  • Wiegartz P, Gyoerkoe K. Develop relaxation skills. In: The Pregnancy and Postpartum Anxiety Workbook: Practical Skills to Help You Overcome Anxiety, Worry, Panic Attacks, Obsessions, and Compulsions. New Harbinger Publications, CA, USA, 36–37 (2009).
  • Phillips KM, Antoni MH, Lechner SC, Blomberg BB, Llabre MM, Avisar E. Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom. Med.70(9), 1044–1049 (2008).
  • Vliegen N, Luyten P, Meurs P, Cluckers G. Adaptive and maladaptive dimensions of relatedness and autonomy: relationship with postpartum anxiety and depression. Pers. Indiv. Dif.41, 395–406 (2006).
  • Grazioli R, Terry DJ. The role of cognitive vulnerability and stress in the prediction of postpartum depressive symptomatology. Br. J. Clin. Psychol.39(Pt 4), 329–347 (2000).
  • Orr ST. Social support and pregnancy outcome: a review of the literature. Clin. Obstet. Gynecol.47(4), 842–855 (2004).
  • Cox JE, Buman M, Valenzuela J, Joseph NP, Mitchell A, Woods ER. Depression, parenting attributes, and social support among adolescent mothers attending a teen tot program. J. Pediatr. Adolesc. Gynecol.21(5), 275–281 (2008).
  • Wolman WL, Chalmers B, Hofmeyr GJ, Nikodem VC. Postpartum depression and companionship in the clinical birth environment: a randomized, controlled study. Am. J. Obstet. Gynecol.168(5), 1388–1393 (1993).
  • Elliott SA, Leverton TJ, Sanjack M, Turner H, Cowmeadow P, Hopkins J. Promoting mental health after childbirth: a controlled trial of primary prevention of postnatal depression. Br. J. Clin. Psychol.39(Pt 3), 223–241 (2000).
  • Dennis CL, Kingston D. A systematic review of telephone support for women during pregnancy and the early postpartum period. J. Obstet. Gynecol. Neonatal Nurs.37(3), 301–314 (2008).
  • Leung BM, Kaplan BJ. Perinatal depression: prevalence, risks, and the nutrition link – a review of the literature. J. Am. Diet. Assoc.109(9), 1566–1575 (2009).
  • Freeman MP, Davis M, Sinha P et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J. Affect. Disord.110(1–2), 142–148 (2008).
  • Otto SJ, Houwelingen AC, Antal M et al. Maternal and neonatal essential fatty acid status in phospholipids: an international comparative study. Eur. J. Clin. Nutr.51(4), 232–242 (1997).
  • Oken E, Kleinman KP, Berland WE, Simon SR, Rich-Edwards JW, Gillman MW. Decline in fish consumption among pregnant women after a national mercury advisory. Obstet. Gynecol.102(2), 346–351 (2003).
  • Goyer R, Aposhian V, Arab L et al.Toxicological Effects of Methylmercury. National Academy Press, Washington DC, USA (2000).
  • Oken E, Radesky JS, Wright RO et al. Maternal fish intake during pregnancy, blood mercury levels, and child cognition at age 3 years in a US cohort. Am. J. Epidemiol.167, 1171–1181 (2008).
  • Su KP, Huang SY, Chiu TH et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry69(4), 644–651 (2008).
  • Freeman MP, Hibbeln JR, Wisner KL et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry67(12), 1954–1967 (2006).
  • Freeman MP, Sinha P. Tolerability of omega-3 fatty acid supplements in perinatal women. Prostaglandins Leukot. Essent. Fatty Acids77(3–4), 203–208 (2007).
  • Foran E, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? Arch. Pathol. Lab. Med.127(12), 1603–1605 (2003).
  • Freeman MP. Complementary and alternative medicine for perinatal depression. J. Affect. Disord.112(1–3), 1–10 (2009).
  • Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst. Rev.2, CD003390 (2003).
  • Milman N. Prepartum anaemia: prevention and treatment. Ann. Hematol.87, 949–959 (2008).
  • Vahdat Shariatpanaahi M, Vahdat Shariatpanaahi Z, Moshtaaghi M, Shahbaazi SH, Abadi A. The relationship between depression and serum ferritin level. Eur. J. Clin. Nutr.61(4), 532–535 (2007).
  • Romans SE, Tyas J, Cohen MM et al. Gender differences in the symptoms of major depressive disorder. J. Nerv. Ment. Dis.195, 905–911 (2007).
  • La Coursiere DY, Baksh L, Bloebaum L, Vamer MW. Maternal body mass index and self-reported postpartum depressive symptoms. Matern. Child Health J.10, 385–390 (2006).
  • Carter AS, Baker CW, Brownell KD. Body mass index, eating attitudes, and symptoms of depression and anxiety in pregnancy and the postpartum period. Psychosom. Med.62(2), 264–270 (2000).
  • Lu XY. The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr. Opin. Pharmacol.7, 648–652 (2007).
  • Field T, Hernandez-Reif M, Diego M, Figueiredo B, Schanberg S, Kuhn C. Prenatal cortisol, prematurity and low birthweight. Infant Behav. Dev.29, 268–275 (2006).
  • Gillman MW, Rich-Edwards JW, Huh S, et al. Maternal corticotrophin-releasing hormone levels during pregnancy and offspring adiposity. Obesity (Silver Spring)14, 1647–1653 (2006).
  • Levine MD, Marcus MD. Psychosocial treatment of binge eating disorder: an update. Eat. Disord. Rev.14, (2003).
  • Astrachan-Fletchter E. The Dialectical Behavioral Therapy Skills Workbook for Bulimia. New Harbinger Publications, CA, USA, 200 (2009).
  • DeMoor MHM, Beem AL, Stubbe JH. Regular exercise, anxiety, depression and personality: a population-based study. Prev. Med.42, 273–279 (2006).
  • Blumenthal JA, Babyak MA, Doraiswamy M et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom. Med.69, 587–596 (2007).
  • Freeman MP, Helgason C, Hill R. Selected integrative medicine treatments for depression: considerations for women. J. Am. Med. Womens Assoc.59, 216–224 (2004).
  • Orr ST, James SA, Garry J, Newton E. Exercise participation before and during pregnancy among low-income, urban, black women: the Baltimore Preterm Birth study. Ethn. Dis.16, 909–913 (2006).
  • Koniak-Griffin D. Aerobic exercise, psychological well-being, and physical discomforts during adolescent pregnancy. Res. Nurs. Health17, 253–263 (1994).
  • Heh SS, Huang L, Ho S, Fu Y, Wang L. Effectiveness of an exercise support program in reducing the severity of postnatal depression in Taiwanese women. Birth35(1), 60–65 (2008).
  • Daley A, Jolly K, MacArthur C. The effectiveness of exercise in the management of post-natal depression: systematic review and meta-analysis. Fam. Pract.26, 154–162 (2009).
  • Schlussel MM, DeSouza EB, Reichenheim MD, Kac G. Physical activity during pregnancy and maternal–child health outcomes: a systematic literature review. Cad. Saude Publica24(4), S531–S544 (2008).
  • Gavard JA, Artal R. Effect of exercise on pregnancy outcome. Clin. Obstet. Gynecol.51(2), 467–480 (2008).
  • Artal R, O’Toole M. Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period. Br. J. Sports Med.37, 6–12 (2003).
  • Inskip HM, Crozier SR, Godfrey KM Borland SE, Cooper C, Robinson SM. Women’s compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study. Br. Med. J.338(B481), 1–6 (2009).
  • Pereira MA, Rifas-Shiman SL, Kleinman KP, Rich-Edwards JW, Peterson KE, Gillman MW. Predictors of change in physical activity during and after pregnancy. Am. J. Prev. Med.32(4), 312–319 (2007).
  • Wilkinson S, Huang C, Walker LO Sterling BS, Kim M. Physical activity in low-income postpartum women. J. Nurs. Scholarsh.36(2), 109–114 (2004).
  • Segar ML, Eccles JS, Richardson CR. Type of physical activity goal influences participation in healthy midlife women. Womens Health Issues18, 281–291 (2008).
  • Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum. Psychopharmacol. Clin. Exp.23, 571–585 (2008).
  • Novati A, Roman V, Cetin T et al. Chronically restricted sleep leads to depression-like changes in neurotransmitter receptor sensitivity and neuroendocrine stress reactivity in rats. Sleep31(11), 1579–1585 (2008).
  • Buysee DJ, Angst J, Gamma A, Ajdacic V, Elch D, Rossler W. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep31(4), 473–480 (2008).
  • Neckelman D, Mykletun A, Hahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep30(7), 873–880 (2007).
  • Parry BL, Newton RP. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology25, S102–S108 (2001).
  • Santiago JR, Nolledo MS, Kinzler W, Santiago TV. Sleep and sleep disorders in pregnancy. Ann. Intern. Med.134, 396–408 (2001).
  • Ross LE, Murray BJ, Steiner M. Sleep and perinatal mood disorders: a critical review. Rev. Psychiatr. Neurosci.30(4), 247–256 (2005).
  • Parry BL, Meliska CJ, Sorenson DL et al. Plasma melatonin circadian rhythm disturbances during pregnancy and postpartum in depressed women and women with personal or family histories of depression. Am. J. Psychiatry165(12), 1551–1558 (2008).
  • Goyal D, Gay C, Lee K. Fragmented maternal sleep is more strongly correlated with depressive symptoms than infant temperament at three months postpartum. Arch. Womens Ment. Health.12, 229–237 (2009).
  • Posmontier B. Sleep quality in women with and without postpartum depression. J. Obstet. Gynecol. Neonatal. Nurs.37(6), 722–737 (2008).
  • Armitage R, Flynn H, Hooffman R, Vazquez D, Lopez J, Marcus S. Early developmental changes in sleep in infants: the impact of maternal depression. Sleep32(5), 693–696 (2009).
  • Shirani A, Louis EK. Illuminating rationale and uses for light therapy. J. Clin. Sleep Med.5(2), 155–163 (2009).
  • Oren DA, Wisner KL, Spinelli M et al. An open trial of morning light therapy for treatment of antepartum depression. Am. J. Psychiatry.159(4), 666–669 (2002).
  • Epperson CN, Terman M, Terman JS et al. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J. Clin. Psychiatry65(3), 421–425 (2004).
  • Yonkers KA, Wisner KL, Stewart DE et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetrics and Gynecology. Gen. Hosp. Psychiatry31(5), 403–413 (2009).
  • Kordes-de Vaal JH. Intention and the omission bias: omission perceived as nondecision. Acta Psychol. (Amst.)93(1–3), 161–172 (1996).
  • Marcus SM, Flynn HA. Depression, antidepressant medication, and functioning outcomes among pregnant women. Int. J. Gynecol. Obstet.100(3), 248–251 (2008).
  • Andrade SE, Gurwitz JH, Davis RL et al. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol.191, 398–407 (2004).
  • Lattimore KA, Donn SM, Kaciroti N et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J. Perinatol.25, 595–604 (2005).
  • Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. J. Psychiatr. Neurosci.26(1), 41–48 (2001).
  • Newport DJ, Brennan PA, Green P et al. Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentation. BJOG115(6), 681–688 (2008).
  • Gartlehner G, Gaynes BN, Hansen RA et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann. Int. Med.149(10), 734–750 (2008).
  • Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive–compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J. Clin. Psychiatry65(10), 1365–1371 (2004).
  • Bodnar LM, Dunder KR, Wisner KL. Treatment with selective serotonin reuptake inhibitors during pregnancy: deceleration of weight gain because of depression or drug? Am. J. Psychiatry163, 6 (2006).
  • Laimer M, Kramer-Reinstadler K, Rauchenzauner M et al. Effect of mirtazapine treatment on body composition and metabolism. J. Clin. Psychiatry67(3), 421–424 (2006).
  • Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int. J. Clin. Psychopharm.21(Suppl. 1), S25–S29 (2006).
  • Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum. Psychopharmacol.20(8), 533–559 (2005).
  • Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am. J. Med.119(2), 113–116 (2006).
  • Alper K, Schwartz KA, Kolls RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol. Psychiatry62(4), 345–354 (2007).
  • Toh S, Mitchell AA, Louik C et al. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am. J. Psychiatry166(3), 320–328 (2009).
  • Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann. Pharmacother.36(10), 1577–1589 (2002).
  • Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J. Clin. Psychiatry67(2), 204–210 (2006).
  • Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol. Drug Saf.14, 823–827 (2005).
  • Louik C, Lin AE, Werler MM et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N. Engl. J. Med.356(26), 2675–2683 (2007).
  • Diav-Citrin O, Shechtman S, Weinbaum D et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br. J. Clin. Pharmacol.66(5), 695–705 (2008).
  • Cole JA, Ephross SA, Cosmatos IS et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Saf.16, 1075–1085 (2007).
  • Berard A, Ramos E, Rey E et al. First trimester exposure to paroxetine and risk of cardiac malformations in infant: the importance of dosage. Birth Defects Res. B Dev. Reprod. Toxicol.80(1), 18–27 (2007).
  • Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol. Med.5, 1–11 (2010).
  • Einarson A, Pistelli A, DeSantis M et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am. J. Psychiatry165, 749–752 (2008).
  • Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics113(2), 368–375 (2004).
  • Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med.354(6), 579–587 (2006).
  • Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf.17(8), 801–806 (2008).
  • Andrade SE, McPhillips H, Loren D et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf.18(3), 246–252 (2009).
  • Fornaro E, Li D, Pan J et al. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am. J. Respir. Crit. Care Med.176, 1035–1040 (2007).
  • Broy P, Berard A. Gestational exposure to antidepressants and the risk of spontaneous abortion: a review. Curr. Drug. Deliv.7(1), 76–92 (2009).
  • Wisner KL, Sit DKY, Hanusa BH et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am. J. Psychiatry166(5), 557–566 (2009).
  • Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry159, 2055–2061 (2002).
  • Wikner BN, Stiller CO, Källén B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol. Drug Saf.16(9), 988–994 (2007).
  • Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr. Serv.53(1), 39–49 (2002).
  • Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol. Drug Saf.16(11), 1203–1210 (2007).
  • Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case–control teratologic study of nitrazepam, medazepam, tofisopam, alprazolam and clonazepam treatment during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol.101(2), 147–154 (2002).
  • Acs N, Bánhidy F, Horváth-Puhó E, Czeizel AE. Maternal panic disorder and congenital abnormalities: a population-based case–control study. Birth Defects Res. A Clin. Mol. Teratol.76(4), 253–261 (2006).
  • Kanto J, Aaltonen L, Linkka P, Maenpaa K. Transfer of lorazepam and its conjugate across the human placenta. Acta Pharmacol. Toxicol. (Copenh.)47, 130–134 (1980).
  • McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod. Toxicol.8, 461–475 (1994).
  • Cohen LS. Treatment of bipolar disorder during pregnancy. J. Clin. Psychiatry68(Suppl. 9), 4–9 (2007).
  • Einarson A. Antipsychotic medication (safety/risk) during pregnancy and breastfeeding. Curr. Womens Health Rev.6(1), 34–38 (2010).
  • O’Hara M. Postpartum depression: what we know. J. Clin. Psychol.65(12), 1258–1260 (2009).
  • Dennis CL, Ross LE, Grigoriadis S. Psychosocial and psychological interventions for treating antenatal depression. Cochrane Database Syst. Rev.3, 1–17 (2007).
  • Spinelli MG, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am. J. Psychiatry160(3), 555–562 (2003).
  • Grote NK, Swartz HA, Geibel SL, Zuckoff A, Houck PR, Frank E. A randomized controlled trial of culturally relevant brief interpersonal psychotherapy for perinatal depression. Psychiatr. Serv.60(3), 313–321 (2009).
  • O’Hara MW, Stuart S, Gormal LL, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. Arch. Gen. Psychiatry57, 1039–1045 (2000).
  • Spinelli MG. Prevention of postpartum mood disorders. In: Postpartum Mood Disorders. Miller LJ (Ed.). American Psychiatric Press, Washington DC, USA, 217–235 (1999).
  • Zlotnick C, Miller IW, Pearlstein T, Howard M, Sweeney P. A preventive intervention for pregnant women on public assistance at risk for postpartum depression. Am. J. Psychiatry163(8), 1443–1445 (2006).
  • Misri S, Kendrick K. Treatment of perinatal mood and anxiety disorders: a review. Can. J. Psychiatry52(8), 489–498 (2004).
  • Hensley PL, Nadiga D, Uhlenhuth EH. Long-term effectiveness of cognitive therapy in major depressive disorder. Depress. Anxiety20, 1–7 (2004).
  • Cho HJ, Kwon JH, Lee JJ. Antenatal cognitive–behavioral therapy for prevention of postpartum depression: a pilot study. Yonsei Med. J.49, 553–562 (2008).
  • Chabrol H, Teissedre F, Sanit JM, Teisseyre N, Roge B, Mullet E. Prevention and treatment of post-partum depression: a controlled randomized study on women at risk. Psychol. Med.32(6), 1039–1047 (2002).
  • Austin MP, Frilingos M, Lumley J, Dazi-Pavlovic D. Brief antenatal cognitive behavior therapy group intervention for the prevention of postnatal depression and anxiety: a randomized controlled trial. J. Affect. Disord.105, 35–44 (2008).
  • Milgrom J, Negri LM, Bemmill AW, McNeil M, Martin P. A randomized controlled trial of psychological interventions for postnatal depression. Br. J. Clin. Psychol.44, 529–524 (2005).
  • Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive–behavioural counseling in the treatment of postnatal depression. Br. Med. J.314, 932–936 (1997).
  • Apfel RJ, Handel MH. Couples therapy for postpartum mood disorders. In: Postpartum Mood Disorders. Miller LJ (Ed.). American Psychiatric Press, Washington DC, USA, 163–178 (1999).
  • Barbato A, D’Avanzo B. Efficacy of couple therapy as a treatment for depression: a meta-analysis. Psychiatr. Q.79, 121–132 (2008).
  • South SC, Krueger RF. Marital quality moderates genetic and environmental influences on the internalizing spectrum. J. Abnorm. Psychol.117(4), 826–837 (2008).
  • Barbato A, D’Avanzo B. Marital therapy for depression (review). Cochrane Database Syst. Rev.2, 1–27 (2006).
  • Misri S, Kostaras X, Fox D, Kostaras D. The impact of partner support in the treatment of postpartum depression. Can. J. Psychiatry.45, 554–558 (2000).
  • Dwight-Johnson M, Unutzer J, Sherbourne C, Tang L, Wells KB. Can quality improvement programs for depression in primary care address patient preferences for treatment? Med. Care39(9), 934–944 (2001).
  • Binder ED, Newport J, Zach ED et al. A serotonin transporter gene polymorphism predicts peripartum depressive symptoms in an at-risk psychiatric cohort. J. Psychiatr. Res. DOI: 10.1016/j.jpsychires.2009.12.001 (2009) (Epub ahead of print).
  • Maes M, Verkerk R, Bonaccorso S et al. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci.71(16), 1837–1848 (2002).
  • Zandi PP, Judy JT. The promise and reality of pharmacogenetics in psychiatry. Psychiatr. Clin. N. Am.33(1), 181–224 (2010).
  • Dimidjian S, Davisk J. Newer variations of cognitive–behavioral therapy: behavioral activation and mindfulness-based cognitive therapy. Curr. Psychiatry Rep.11(6), 453–458 (2009).
  • Cosimo Melcangi R, Gargia-Segura LM. Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection. Horm. Behav.57(1), 2–11 (2010).
  • Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J. Clin. Invest.119(4), 717–725 (2009).
  • Posse S, Fitzgerald D, Gao K et al. Real-time fMRI of temporolimbic regions detects amygdale activation during single-trial self-induced sadness. Neuroimage18(3), 760–768 (2003).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.